Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving Average – Should You Sell?

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.60 and traded as high as $1.79. Coherus Oncology shares last traded at $1.74, with a volume of 793,783 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CHRS. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Oppenheimer assumed coverage on Coherus Oncology in a report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $5.51.

Coherus Oncology Stock Performance

The business has a 50 day simple moving average of $1.83 and a 200 day simple moving average of $1.60. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.47 and a quick ratio of 1.45. The company has a market cap of $259.31 million, a price-to-earnings ratio of 1.18 and a beta of 1.03.

Coherus Oncology (NASDAQ:CHRS) last announced its earnings results on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The business had revenue of $12.75 million during the quarter, compared to analyst estimates of $14.09 million. Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. As a group, equities analysts forecast that Coherus Oncology, Inc. will post -1.05 EPS for the current year.

Hedge Funds Weigh In On Coherus Oncology

Institutional investors have recently modified their holdings of the stock. Quarry LP bought a new stake in shares of Coherus Oncology during the third quarter valued at approximately $26,000. Blair William & Co. IL acquired a new position in Coherus Oncology during the 4th quarter worth $27,000. Bronte Capital Management Pty Ltd. acquired a new position in Coherus Oncology during the 4th quarter worth $27,000. China Universal Asset Management Co. Ltd. bought a new position in Coherus Oncology in the 4th quarter valued at $28,000. Finally, Kestra Private Wealth Services LLC bought a new position in Coherus Oncology in the 4th quarter valued at $28,000. 72.82% of the stock is owned by institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.